Skip to content

Short-term Effect of Rho-kinase Inhibitor on Retinal Circulation

Short-term Effect of Rho-kinase Inhibitor on Retinal Circulation

Status
UNKNOWN
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04234932
Enrollment
10
Registered
2020-01-21
Start date
2020-01-06
Completion date
2021-01-31
Last updated
2020-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma, Open-Angle

Brief summary

Investigate changes in optical coherence tomography angiography of the optic nerve and macula following topical instillation of commercial preparations of netarsudil 0.02% ophthalmic solution.

Interventions

Topical instillation of commercial preparations of netarsudil 0.02% ophthalmic solution (Rhopressa and Roclatan)

Sponsors

University of the Incarnate Word
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Normal ocular health

Exclusion criteria

* Females who are or may be pregnant or who are nursing * Uncontrolled hypertension * Allergy to netarsudil or latanoprost

Design outcomes

Primary

MeasureTime frameDescription
Peripapillary capillary perfusion density90 minutesMean change in peripapillary capillary perfusion as assessed using optical coherence tomography angiography

Secondary

MeasureTime frameDescription
Macular capillary perfusion density90 minutesMean change in macular capillary perfusion as assessed using optical coherence tomography angiography

Countries

United States

Contacts

Primary ContactMary Jo Bilicek
bilicek@uiwtx.edu210-805-3565

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026